Maravai LifeSciences Holdings, Inc.

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.7 ^USD	+1.58%		+5.48%	+17.56%

Apr. 18	Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego	MT
Apr. 10	Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	MT

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024

February 22, 2024 at 04:05 pm EST

Maravai LifeSciences Holdings, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue to be in the range of $265.0 million to $285.0 million.

Latest news about Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego	Apr. 18	MT
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	Apr. 10	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating	Apr. 08	MT
Transcript : Maravai LifeSciences Holdings, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 02:15 PM	Mar. 19
Sector Update: Health Care Stocks Rise in Late Afternoon	Feb. 23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 23	MT
Top Midday Gainers	Feb. 23	MT
Sector Update: Health Care	Feb. 23	MT
Maravai LifeSciences Shares Surge After Price Target Raises, Q4 Beat	Feb. 23	MT
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating	Feb. 23	MT
Stifel Trims Price Target on Maravai LifeSciences to $10 From $11, Maintains Buy Rating	Feb. 23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	Feb. 23	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Feb. 23	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday	Feb. 23	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating	Feb. 23	MT
Top Premarket Gainers	Feb. 23	MT
Maravai LifeSciences' Q4 Adjusted Earnings, Revenue Decline	Feb. 23	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q4 Revenue $74.1M, vs. Street Est of $64.3M	Feb. 22	MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Posts Q4 EPS $0.01, vs. Street Est of $-0.01	Feb. 22	MT
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 22	CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay	Feb. 13	MT
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
BofA Securities Upgrades Maravai LifeSciences to Buy From Neutral	Dec. 12	MT

Chart Maravai LifeSciences Holdings, Inc.

Duration

Period

Chart Maravai LifeSciences Holdings, Inc.

More charts

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Maravai LifeSciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.7 USD

Average target price

9.785 USD

Spread / Average Target

+27.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M
CURIOX BIOSYSTEMS CO., LTD	+13.32%	332M

Bio Diagnostics & Testing